Published in Gene Therapy Weekly, March 24th, 1997
Lark's senescence gene research program has moved to a new phase with direct testing of tumor derived cell lines to identify potential mutations in its previously announced candidate senescence gene linked to cellular aging and cancer. The research helps identify the types of mutations in the gene which could contribute to cell immortalization, a prerequisite of cancer.
Previous research has firmly established that four genetic pathways, known as Complementation Groups A, B, C, and D work together to prevent cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.